BACKGROUND: Elevated plasma fibrinogen is associated with arterial thrombosis in humans and promotes thrombosis in mice by increasing fibrin formation and thrombus fibrin content. Fibrinogen is composed of six polypeptide chains: (Aα, Bβ, and γ)2. Alternative splicing of the γ chain leads to a dominant form (γA/γA) and a minor species (γA/γ'). Epidemiological studies have detected elevated γA/γ' fibrinogen in patients with arterial thrombosis, suggesting that this isoform promotes thrombosis. However, in vitro data show that γA/γ' is anticoagulant due to its ability to sequester thrombin and suggest its expression is upregulated in response to inflammatory processes. OBJECTIVE: To determine whether γA/γ' fibrinogen is prothrombotic in vivo. METHODS: We separated γA/γA and γA/γ' fibrinogen from human plasma-purified fibrinogen and determined the effects on in vitro plasma clot formation and on in vivo thrombus formation and circulating thrombin-antithrombin complexes in mice. RESULTS AND CONCLUSIONS: Both γA/γA and γA/γ' fibrinogen were cleaved by murine and human thrombin and were incorporated into murine and human clots. When γA/γA or γA/γ' was spiked into plasma, γA/γA increased the fibrin formation rate to a greater extent than γA/γ'. In mice, compared to controls, γA/γA infusion shortened the time to carotid artery occlusion, whereas γA/γ' infusion did not. Additionally, γA/γ' infusion led to lower levels of plasma thrombin-antithrombin complexes following arterial injury, whereas γA/γA infusion did not. These data suggest that γA/γ' binds thrombin in vivo and decreases prothrombotic activity. Together, these findings indicate that elevated levels of γA/γA fibrinogen promote arterial thrombosis in vivo, whereas γA/γ' does not.
BACKGROUND: Elevated plasma fibrinogen is associated with arterial thrombosis in humans and promotes thrombosis in mice by increasing fibrin formation and thrombus fibrin content. Fibrinogen is composed of six polypeptide chains: (Aα, Bβ, and γ)2. Alternative splicing of the γ chain leads to a dominant form (γA/γA) and a minor species (γA/γ'). Epidemiological studies have detected elevated γA/γ' fibrinogen in patients with arterial thrombosis, suggesting that this isoform promotes thrombosis. However, in vitro data show that γA/γ' is anticoagulant due to its ability to sequester thrombin and suggest its expression is upregulated in response to inflammatory processes. OBJECTIVE: To determine whether γA/γ' fibrinogen is prothrombotic in vivo. METHODS: We separated γA/γA and γA/γ' fibrinogen from human plasma-purified fibrinogen and determined the effects on in vitro plasma clot formation and on in vivo thrombus formation and circulating thrombin-antithrombin complexes in mice. RESULTS AND CONCLUSIONS: Both γA/γA and γA/γ' fibrinogen were cleaved by murine and humanthrombin and were incorporated into murine and human clots. When γA/γA or γA/γ' was spiked into plasma, γA/γA increased the fibrin formation rate to a greater extent than γA/γ'. In mice, compared to controls, γA/γA infusion shortened the time to carotid artery occlusion, whereas γA/γ' infusion did not. Additionally, γA/γ' infusion led to lower levels of plasma thrombin-antithrombin complexes following arterial injury, whereas γA/γA infusion did not. These data suggest that γA/γ' binds thrombin in vivo and decreases prothrombotic activity. Together, these findings indicate that elevated levels of γA/γA fibrinogen promote arterial thrombosis in vivo, whereas γA/γ' does not.
Authors: Rehana S Lovely; Steven C Kazmierczak; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; David H Farrell Journal: Clin Chem Date: 2010-03-26 Impact factor: 8.327
Authors: E G van den Herik; E Y L Cheung; L M L de Lau; H M den Hertog; F W G Leebeek; D W J Dippel; P J Koudstaal; M P M de Maat Journal: Thromb Res Date: 2011-09-13 Impact factor: 3.944
Authors: Evita G van den Herik; Elim Y L Cheung; Lonneke M L de Lau; Heleen M den Hertog; Frank W Leebeek; Diederik W J Dippel; Peter J Koudstaal; Moniek P M de Maat Journal: Thromb Haemost Date: 2010-12-06 Impact factor: 5.249
Authors: Robert A Campbell; Katherine A Overmyer; Craig H Selzman; Brett C Sheridan; Alisa S Wolberg Journal: Blood Date: 2009-10-01 Impact factor: 22.113
Authors: Bethany L Walton; Marcus Lehmann; Tyler Skorczewski; Lori A Holle; Joan D Beckman; Jeremy A Cribb; Micah J Mooberry; Adam R Wufsus; Brian C Cooley; Jonathan W Homeister; Rafal Pawlinski; Michael R Falvo; Nigel S Key; Aaron L Fogelson; Keith B Neeves; Alisa S Wolberg Journal: Blood Date: 2017-03-01 Impact factor: 22.113
Authors: David H Farrell; Elizabeth A Rick; Elizabeth N Dewey; Martin A Schreiber; Susan E Rowell Journal: Am J Surg Date: 2019-12-28 Impact factor: 2.565